HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NAD Could Jog Cognitive Benefit Supplement Firm's Memory With FTC Call

This article was originally published in The Rose Sheet

Executive Summary

NAD refers UltraMax Health's supplement claim to the FTC after it fails to provide substantiation. CRN emphasizes claims alone are not the problem, but the firm's failure to provide substantiation.

You may also be interested in...



Avantius Launches Supplement After Study Finds Formulation Slowed Alzheimer’s Progression

Memory Health supplement was developed and is launching in the US after a small European study of Alzheimer’s patients finds improvement in patients taking a carotenoid/omega-3 combination, says marketer Avantius Group. A larger-scale, double blinded clinical study is underway in Europe.

'Enhanced Brain Function' Supplement Sales Only A Memory After NAD Review

Council of Better Business Bureau's industry self-regulation arm says UltraMax Health, after previously not responding to a request for evidence supporting Max Synapse online ad claims, stated in writing that it stopped using the claims and no longer is selling the product.

Supplement Claims Targeting Elderly, Weight Conscious Top FTC Priorities

Dubious supplement ad claims that have driven FTC enforcement in the sector for some time likely will continue as three commission seats are filled, says advertising practices official Richard Cleland.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134043

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel